文献速递免疫规划卫生政策与健康促进慢病防控与筛查

肯尼亚HPV疫苗接种的影响、成本效果与预算影响:一项模型研究

Impact, cost-effectiveness, and budget implications of HPV vaccination in Kenya: A modelling study.
PubMed 文献 · Vaccine · 2023-06-08

研究采用比例结局静态队列模型,评估2020—2029年肯尼亚10岁女孩接种四价HPV疫苗及2020年11—14岁女孩补种活动的预算影响与终身成本效果。结果显示,接种可减少42—60%的宫颈癌病例和死亡;在支付意愿阈值100美元下,最具成本效果的疫苗有100%概率具有成本效果;单剂策略相比不接种可节省成本。

要点

  • HPV疫苗接种可减少42—60%的宫颈癌病例和死亡。
  • 在支付意愿阈值100美元下,最具成本效果的疫苗有100%概率具有成本效果。

核心结论

  • 肯尼亚女孩接种HPV疫苗具有高度成本效果。
  • 与GARDASIL-4相比,替代产品可以以更低的净成本提供相似或更大的健康获益。
  • 随着肯尼亚毕业Gavi支持,需要大量政府资金来达到并维持覆盖率目标。
  • 单剂策略可能以更低的成本获得相似的获益。

研究设计与样本

  • 研究采用比例结局静态队列模型,评估2020—2029年接种10岁女孩的年度预算影响和终身成本效果。
  • 模型包括2020年对11—14岁女孩的补种活动。
  • 研究估计了14个出生队列终身期间接种与不接种情况下宫颈癌病例、死亡、伤残调整生命年(DALY)和医疗成本(政府和社会视角)。
  • 模型输入来自已发表来源和当地利益相关者。

主要发现

  • 在14个评估出生队列的终身期间,估计有320,000例宫颈癌病例和225,000例死亡。
  • HPV疫苗接种可将该负担减少42—60%。
  • 无交叉保护时,CECOLIN净成本最低且成本效果最具吸引力;有交叉保护时,CERVARIX最具成本效果。
  • 在任一情景下,最具成本效果的疫苗在支付意愿阈值100美元(肯尼亚人均国内生产总值的5%)下相比不接种有100%概率具有成本效果。

关键数值与推荐

  • 在支付意愿阈值100美元(肯尼亚人均国内生产总值的5%)下,最具成本效果的疫苗相比不接种有100%概率具有成本效果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sub-Saharan Africa has the highest rate of cervical cancer cases and deaths worldwide. Kenya introduced a quadrivalent HPV vaccine (GARDASIL, hereafter referred to as GARDASIL-4) for ten-year-old girls in late 2019 with donor support from Gavi, the Vaccine Alliance. As Kenya may soon graduate from Gavi support, it is important to evaluate the potential cost-effectiveness and budget impact of the current HPV vaccine, and potential alternatives. METHODS: We used a proportionate outcomes static cohort model to evaluate the annual budget impact and lifetime cost-effectiveness of vaccinating ten-year-old girls over the period 2020-2029. We included a catch-up campaign for girls aged 11-14 years in 2020. We estimated cervical cancer cases, deaths, disability adjusted life years (DALYs), and healthcare costs (government and societal perspective) expected to occur with and without vaccination over the lifetimes of each cohort of vaccinated girls. For each of the four products available globally (CECOLIN©, CERVARIX©, GARDASIL-4©, and GARDASIL-9 ©), we estimated the cost (2021 US$) per DALY averted compared to no vaccine and to each other. Model inputs were obtained from published sources, as well as local stakeholders. RESULTS: We estimated 320,000 cases and 225,000 deaths attributed to cervical cancer over the lifetimes of the 14 evaluated birth cohorts. HPV vaccination could reduce this burden by 42-60 %. Without cross-protection, CECOLIN had the lowest net cost and most attractive cost-effectiveness. With cross-protection, CERVARIX was the most cost-effective. Under either scenario the most cost-effective vaccine had a 100 % probability of being cost-effective at a willingness-to-pay threshold of US$ 100 (5 % of Kenya's national gross domestic product per capita) compared to no vaccination. Should Kenya reach its target of 90 % coverage and graduate from Gavi support, the undiscounted annual vaccine program cost could exceed US$ 10 million per year. For all three vaccines currently supported by Gavi, a single-dose strategy would be cost-saving compared to no vaccination. CONCLUSION: HPV vaccination for girls is highly cost-effective in Kenya. Compared to GARDASIL-4, alternative products could provide similar or greater health benefits at lower net costs. Substantial government funding will be required to reach and sustain coverage targets as Kenya graduates from Gavi support. A single dose strategy is likely to have similar benefits for less cost.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mwenda V, Jalang'o R, Miano C, et al. Impact, cost-effectiveness, and budget implications of HPV vaccination in Kenya: A modelling study. Vaccine. 2023. PMID: 37296015. doi:10.1016/j.vaccine.2023.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。